Prasinezumab

Prasinezumab
Monoclonal antibody
Type?
Targetα-Synuclein
Clinical data
Other namesNEOD002; NEOD-002; PRX002; PRX-002; RG7935; RG-7935; RO7046015; RO-7046015
Identifiers
CAS Number
DrugBank
UNII

Prasinezumab (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names NEOD002, PRX-002, RG-7935, RO-7046015) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which is under development for the treatment of Parkinson's disease.[1][2][3][4] No significant effect on disease progression was seen in a 52-week phase 2 clinical trial.[2] In any case, the trial was extended and development of the drug continues.[2] There have been concerns about research misconduct and data fabrication relevant to prasinezumab.[5] As of May 2024, prasinezumab is in phase 2 clinical trials for Parkinson's disease.[1] It is under development by Prothena Biosciences and Roche.[1]

See also

References

  1. 1 2 3 "Prasinezumab - Prothena Corporation/Roche". AdisInsight. 9 May 2024. Retrieved 26 September 2024.
  2. 1 2 3 Manoutcharian K, Gevorkian G (March 2024). "Recombinant Antibody Fragments for Immunotherapy of Parkinson's Disease". BioDrugs. 38 (2): 249–257. doi:10.1007/s40259-024-00646-5. PMC 10912140. PMID 38280078.
  3. ↑ Lasheen NN, Allam S, Elgarawany A, Aswa DW, Mansour R, Farouk Z (September 2024). "Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders". J Physiol Sci. 74 (1): 46. doi:10.1186/s12576-024-00933-4. PMC 11421184. PMID 39313800.
  4. ↑ Teng JS, Ooi YY, Chye SM, Ling AP, Koh RY (2021). "Immunotherapies for Parkinson's Disease: Progression of Clinical Development". CNS Neurol Disord Drug Targets. 20 (9): 802–813. doi:10.2174/1871527320666210526160926. PMID 34042040.
  5. ↑ Incorvaia, Darren (26 September 2024). "NIH neuroscience leader committed research misconduct, agency investigation finds". Fierce Biotech. Retrieved 26 September 2024.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.